Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Cerevel Therapeutics Inc...

    NASDAQ: CERE · Real-Time Price · USD
    44.96
    0.33 (0.74%)
    At close: Jul 31, 2024, 10:00 PM

    Cerevel Therapeutics Statistics

    Share Statistics

    Cerevel Therapeutics has 182.2M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 182.2M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 94.04%

    Shares Floating

    n/a
    		 77.82M

    Failed to Deliver (FTD) Shares

    n/a
    		 4,782,602

    FTD / Avg. Volume

    n/a
    		 232.56%

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -15.87 and the forward PE ratio is null. Cerevel Therapeutics's PEG ratio is -1.05.

    PE Ratio

    n/a
    		 -15.87

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 10.2

    P/FCF Ratio

    n/a
    		 -19.85

    PEG Ratio

    n/a
    		 -1.05
    Financial Ratio History

    Enterprise Valuation

    Cerevel Therapeutics has an Enterprise Value (EV) of 6.36B.

    EV / Sales

    n/a
    		 0

    EV / EBITDA

    n/a
    		 -14.4

    EV / EBIT

    n/a
    		 -18.58

    EV / FCF

    n/a
    		 -18.38

    Financial Position

    The company has a current ratio of 10.92, with a Debt / Equity ratio of 0.55.

    Current Ratio

    n/a
    		 10.92

    Quick Ratio

    n/a
    		 10.92

    Debt / Equity

    n/a
    		 0.55

    Debt / EBITDA

    n/a
    		 -1.09

    Debt / FCF

    n/a
    		 -1.39

    Interest Coverage

    n/a
    		 -42.33

    Financial Efficiency

    Return on Equity is -64.24% and Return on Invested Capital is -42.96%.

    Return on Equity

    n/a
    		 -64.24%

    Return on Assets

    n/a
    		 -34.81%

    Return on Invested Capital

    n/a
    		 -42.96%

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,219,273.24

    Employee Count

    n/a
    		 355

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 503K

    Effective Tax Rate

    n/a
    		 -0.12%

    Stock Price Statistics

    The stock price has increased by 7.3% in the last 52 weeks. The beta is 1.41, so Cerevel Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.41

    52-Week Price Change

    n/a
    		 7.3%

    50-Day Moving Average

    n/a
    		 41.66

    200-Day Moving Average

    n/a
    		 38.78

    Relative Strength Index (RSI)

    n/a
    		 72.45

    Average Volume (20 Days)

    n/a
    		 2,056,487

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 -5.63M

    Operating Income

    n/a
    		 -447.26M

    Net Income

    n/a
    		 -432.84M

    EBITDA

    n/a
    		 -441.64M

    EBIT

    n/a
    		 -421.77M

    Earnings Per Share (EPS)

    n/a
    		 -2.67
    Full Income Statement

    Balance Sheet

    The company has 990.97M in cash and 480.78M in debt, giving a net cash position of 510.19M.

    Cash & Cash Equivalents

    n/a
    		 990.97M

    Total Debt

    n/a
    		 480.78M

    Net Cash

    n/a
    		 510.19M

    Retained Earnings

    n/a
    		 -1.4B

    Total Assets

    n/a
    		 1.13B

    Working Capital

    n/a
    		 775.47M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -342.3M and capital expenditures -3.81M, giving a free cash flow of -346.11M.

    Operating Cash Flow

    n/a
    		 -342.3M

    Capital Expenditures

    n/a
    		 -3.81M

    Free Cash Flow

    n/a
    		 -346.11M

    FCF Per Share

    n/a
    		 -2.14
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    CERE does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -6.3%

    FCF Yield

    n/a
    		 -5.04%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for CERE.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 6.28

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist